Orthofix Medical Hits 52-Week Low at $9.16 Amidst Ongoing Struggles

Orthofix Medical, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 9.16 as of May 27, 2026. This decline marks a significant downturn for the stock, which has seen a return of -28.84% over the past year. The company's market capitalization stands at USD 477 million, reflecting its position within the microcap category. Despite the challenging market conditions, Orthofix maintains a debt-to-equity ratio of 0.22, indicating a relatively low level of debt compared to equity. However, the company has reported a negative return on equity of -27.08%, highlighting ongoing financial difficulties. The stock's price-to-book ratio is currently at 1.08, suggesting that it is trading close to its book value. In terms of institutional investment, Orthofix has high institutional holdings at 100%, which may provide some stability amid its recent performance challenges. The stock's 52-week high was recorded at USD 16.99, underscoring the volatility it has experienced over the past year.